Non-inferiority trials: the 'at least as good as' criterion

被引:61
作者
Laster, LL
Johnson, MF
机构
[1] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA
[2] PharmaNet Inc, Carnegie Ctr 504, Princeton, NJ 08540 USA
关键词
non-inferiority; sample size; hypothesis testing; confidence interval; ratio estimator;
D O I
10.1002/sim.1137
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
To demonstrate in a clinical trial that a new or experimental therapy (et) is 'at least as good as' a standard therapy (st), a statistical test or confidence interval procedure must rule out clinical inferiority with a high probability. The term 'at least as good as' implies equivalent but not necessarily superior efficacy. As it is statistically impossible to demonstrate equivalence (that is, prove the null hypothesis of no difference), Blackwelder proposed a one-sided significance test to reject the null hypothesis that standard therapy is better than experimental therapy by a clinically acceptable amount, (delta(BW). In this paper, Blackwelder's approach is redefined in terms of the ratio of two means (R-True= mu(et)/mu(st)) based on a continuous variate with higher values denoting greater improvement. The ratio-based equivalents to Blackwelder's hypotheses will be shown. The ratio parameter has the benefit of being available as a dimensionless percentage, not tied to a specified difference in means. Thus, a study can be sized to assure, with high probability, that the experimental therapy is 'at least' (R-LB x 100) per cent as effective as' the standard therapy, where RLB is the selected lower bound on the percentage effectiveness. A practical rationale is given for defining non-inferiority as a high fraction or percentage of the standard drug's efficacy, both in terms of statistical efficiency and medical relevance. For most typical 'at least as good as' applications (when R-LB < R-True less than or equal to 1), the ratio formatted test of H-0 : R-True less than or equal to R-LB is shown to be more efficient than Blackwelder's test of H-0 : mu(st) - mu(et) greater than or equal to delta(BW), thereby requiring smaller sample sizes to detect the directionally based non-null alternatives contained in H-1 : mu(et)/mu(st) > R-LB or, equivalently, mu(st) / mu(et) < delta(BW). Further, when R-True = 1.0, tests of Blackwelder's hypotheses, their ratio-based equivalents and conventional superiority can be evaluated for comparative efficiency. Testing H-0 : R-True less than or equal to R-LB with singlesided critical region of size alpha, versus H-1 : R-True > R-LB, is shown to be more efficient than excluding RLB from the lower limit of a 100(1-2oc) per cent two-sided symmetric confidence interval centred by h. Relevant examples will be presented. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:187 / 200
页数:14
相关论文
共 28 条
[1]   CONSIDERATION OF INDIVIDUAL BIOEQUIVALENCE [J].
ANDERSON, S ;
HAUCK, WW .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1990, 18 (03) :259-273
[2]  
Berger RL, 1996, STAT SCI, V11, P283
[3]   SAMPLE-SIZE GRAPHS FOR PROVING THE NULL HYPOTHESIS [J].
BLACKWELDER, WC ;
CHANG, MA .
CONTROLLED CLINICAL TRIALS, 1984, 5 (02) :97-105
[4]   PROVING THE NULL HYPOTHESIS IN CLINICAL-TRIALS [J].
BLACKWELDER, WC .
CONTROLLED CLINICAL TRIALS, 1982, 3 (04) :345-353
[5]  
Brown LD, 1997, ANN STAT, V25, P2345
[6]   The distribution of the index in a normal bivariate population. [J].
Fieller, EC .
BIOMETRIKA, 1932, 24 :428-440
[7]  
Holmgren E B, 1999, J Biopharm Stat, V9, P651, DOI 10.1081/BIP-100101201
[8]   The validity of the test of individual equivalence ratios [J].
Hwang, JTG ;
Wang, WZ .
BIOMETRIKA, 1997, 84 (04) :893-900
[9]  
Lehmann E., 1959, TESTING STAT HYPOTHE
[10]  
MAKUCH R, 1978, CANCER TREAT REP, V62, P1037